Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B38-CAP (rbACE2) for COVID-19
NCT04375046Phase 1Unknown
- Sponsor
- Kafrelsheikh University
- Start
- Jul 2021
- Primary completion
- Aug 2021
- Modality
- Replacement Enzymes
01
Overview
Phase 1, randomised, open-label trial of Recombinant bacterial ACE2 receptors-like enzyme in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Kafrelsheikh University. Primary endpoints: Time course of body temperature (fever) at 14 days and Viral load over time at 14 days. Status: unknown.
02
Drugs
Recombinant bacterial ACE2 receptors-like enzyme
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04375046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04375046.